Payment overview · 2025
General Payments
$970.25
44 reported records · 13 companies
Healthcare provider profile · identity verified
Lawrence A Mora, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1205851615
Verified facts
What the public records show
CMS Open Payments records show Lawrence A Mora, MD received $970.25 in general payments during 2025 across 44 reported records.
Indivior Inc. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $213.32 | 22.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.75 | 20.7% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $146.15 | 15.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.41 | 8.9% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $77.17 | 8.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.13 | 4.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.06 | 4.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.46 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.79 | 3.6% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.16 | 2.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.99 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.14 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $970.25 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $213.32 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $172.36 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $146.15 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $86.41 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.41 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $77.17 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $26.90 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 93 |
| Metformin Hcl | Metformin Hcl | 245 | 77 |
| Lisinopril | Lisinopril | 244 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 53 |
| Gabapentin | Gabapentin | 178 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 48 |
| Lorazepam | Lorazepam | 163 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 48 |
| Losartan Potassium | Losartan Potassium | 146 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 40 |
| Omeprazole | Omeprazole | 143 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 31 |
| Simvastatin | Simvastatin | 118 | 34 |
| Furosemide | Furosemide | 111 | 32 |
| Meloxicam | Meloxicam | 106 | 26 |
| Trazodone Hcl | Trazodone Hcl | 105 | 23 |
| Alprazolam | Alprazolam | 93 | 17 |
| Glipizide | Glipizide | 91 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 27 |
| Carvedilol | Carvedilol | 68 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 24 |
| Ibuprofen | Ibuprofen | 60 | 21 |
| Januvia | Sitagliptin Phosphate | 60 | 12 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 15 |
| Celecoxib | Celecoxib | 55 | 12 |
| Potassium Chloride | Potassium Chloride | 55 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 14 |
| Temazepam | Temazepam | 55 | suppressed |
| Famotidine | Famotidine | 52 | 15 |
| Naproxen | Naproxen | 51 | 24 |
| Atenolol | Atenolol | 49 | 16 |
| Jardiance | Empagliflozin | 49 | 13 |
| Alendronate Sodium | Alendronate Sodium | 48 | 18 |
| Sertraline Hcl | Sertraline Hcl | 48 | 18 |
| Allopurinol | Allopurinol | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 13 |
| Benazepril Hcl | Benazepril Hcl | 43 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 15 |
| Eliquis | Apixaban | 40 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 12 |
| Ozempic | Semaglutide | 39 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Clarithromycin | Clarithromycin | 36 | 26 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Ibu | Ibuprofen | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 12 |
| Finasteride | Finasteride | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Risperidone Odt | Risperidone | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $970.25 · 44 records | Indivior Inc. | AIRSUPRA, AREXVY, BREZTRI, KEVEYIS, Kerendia, LOREEV XR, MAVYRET, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VIVITROL, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error